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The anticancer drug tamoxifen when introduced into phospholipid liposomes during their preparation i hibited Fe(III)-ascorbate induced lipid 
peroxidation to a greater extent han similarly introduced cholesterol. Ergosterol was equipotent with tamoxifen, but much less effective than 4- 
hydroxytamoxifen. Possible mechanisms underlying these ffects are discussed inrelation to structural mimicry of the sterols by these triphenylethy- 
lene drugs as membrane stabilizers against lipid peroxidation. 
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1. INTRODUCTION 
Tamoxifen is an antioestrogen drug (one of  a series of  
triphenylethylene compounds),  which is widely used in 
the chemotherapy of  breast cancer [1]. 4-Hydro- 
xytamoxifen is produced by the metabolism of  tamox- 
ifen via cytochrome P-450 action in humans [2-6]. We 
have recently reported that tamoxifen and 4-hydro- 
xytamoxifen are antioxidants in that they are potent in- 
hibitors of  lipid peroxidation in microsomal and pre- 
formed liposomal membrane systems when added in the 
carrier solvent ethanol [7]. However, the chemical 
structure of  tamoxifen (Fig. 1) indicates that it is unlike- 
ly to act as a chain-breaking antioxidant because the 
compound contains no easily donatable hydrogen 
atom. Furthermore, chain-breaking antioxidants usual- 
ly introduce a lag period into the peroxidation time- 
course and this was not observed for tamoxifen or 
4-hydroxytamoxifen, even though the latter compound 
possesses a potentially donatable hydrogen atom [7]. 
Cholesterol when introduced into phospholipid 
l iposomes [8-11] during their preparation has been 
reported to inhibit membrane lipid peroxidation ap- 
parently by a membrane stabilization effect [12]. In- 
hibition o f  lipid peroxidation by 17/3-oestradiol in- 
troduced into liposomes has also been reported [13]. 
Using this same experimental procedure we now report 
that not only cholesterol and 17/3-oestradiol but also 
tamoxifen, 4-hydroxytamoxifen a d ergosterol, which 
replaces cholesterol in plant and fungal membranes, 
can be individually introduced into ox-brain phospho- 
lipid liposomes, where each decreases the susceptibility 
of  the liposomes to lipid peroxidation by a 
characteristic amount.  
We therefore suggest that tamoxifen and 4-hydro- 
xytamoxifen may act as structural mimics of  cholesterol 
and ergosterol (see Fig. 1) and thus may exert their 
reported antioxidant action [7] by a similar membrane 
stabilizing effect, which we observe as an inhibition o f  
lipid peroxidation. 
2. MATERIALS  AND METHODS 
2.1. Preparation of Liposomes 
Liposomes were prepared with and without he introduction of the 
compounds shown in Fig. I, as described previously for cholesterol 
[12]. Ox-brain phospholipid was dissolved in chloroform to give a 
final concentration of 5 mg/ml, and a 0.8 ml aliquot was taken and 
mixed with an equal volume of cholesterol, ergosterol, tamoxifen or 
4-hydroxytamoxifen taken from stock solutions in chloroform or, in 
the case of 17/3-oestradiol in methanol-chloroform 1:2 (v/v), to pro- 
vide the concentration range required for each of these compounds. 
The organic solvents were then completely evaporated ina stream of 
nitrogen. The residue was suspended in 0.8 ml of phosphate buffered 
saline (140 mM NaC1, 2.7 mM KC1, 16 mM Na2HPO4 and 2.9 mM 
KHzPO4) at pH 7.4 and after the addition of small glass beads was 
sonicated in a water-bath sonicator (containing ice) and vortexed. The 
resulting liposomes were left to stand in sealed nitrogen-flushed bot- 
tles at 4°C for 1 h prior to use. 
Ox-brain phospholipid, cholesterol, ergosterol, tamoxifen and 17f3- 
oestradiol were purchased from Sigma. 4-Hydroxytamoxifen was 
kindly supplied by ICI Pharmaceuticals p c. Purity was at least 99%. 
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2.2. Peroxidation of Liposomes 
Reaction mixtures (final volume 1.0 ml) contained liposomes (0.5 
mg in 0.1 ml of phosphate buffered saline), phosphate buffered saline 
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Fig. 1. Structural mimicry by tamoxifen and 4-hydroxytamoxifen of 
the sterols cholesterol, ergosterol and 17/~-oestradiol. 
pH 7.4 (0.5 ml) and water (0.2 ml). Peroxidation was started by ad- 
ding freshly prepared aqueous olutions of FeCI3 (0.1 ml) and ascor- 
bate (0.1 ml) to give a final concentration of 100/~M of each. Incuba- 
tions were carried out at 37°C for 20 min. The extent of lipid perox- 
idation was measured by the formation of thiobarbituric acid-reactive 
substances (TBARS) as described in [14]. HC1 (0.5 ml of 25% v/v) 
was added to each reaction mixture, followed by 0.5 ml of thiobar- 
bituric acid solution (1% w/v in 50 mM sodium hydroxide). After 
heating at 80°C for 30 min the chromagen was extracted with 2 ml of 
butan-l-ol  and the A5~2 of the upper (organic) layer was measured. 
3. RESULTS 
Liposomes formed from ox-brain phospholipids act 
as a model membrane (lipid bilayer) system, which in 
the presence of Fe(III) and ascorbate at pH 7.4 is rapid- 
ly peroxidize d [11] as measured by the TBA test. The 
compound/phospholipid ratios were expressed inmolar 
form using an average molecular weight for the 
phospholipid based on the reported phospholipid com- 
position [12]. The data in Fig. 2, expressed therefore as 
molar ratios (phospholipid at 5 mg/ml), show that 
tamoxifen, introduced into liposomes over the concen- 
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Fig. 2. Inhibition of lipid peroxidation by the compounds, (o) 
cholesterol, ( • ) tamoxifen, (.) ergosterol, ( [] ) 4-hydroxytamoxifen 
and ( • ) 17~-oestradiol each introduced into liposomes during their 
preparation. Results are mean +_ SD, n = 6-9 
tration range 0.01-8 mg/ml, inhibited lipid peroxida- 
tion to approximately the same extent as did ergosterol 
(0.01-4 mg/ml). Cholesterol (0.01-8 mg/ml) was a 
much less potent inhibitor than tamoxifen, whereas 
4-hydroxytamoxifen (0.005-2 mg/ml) and 17B-oestra- 
diol (0.005-4 mg/ml) were approximately equipotent. 
The latter two compounds were both more potent in- 
hibitors of peroxidation than tamoxifen (see Fig. 2). 
This inhibitory ability can be expressed as the IC50 
values derived for the compounds tested (see Table I). 
The results how that the concentration (or molar ratio) 
of tamoxifen or ergosterol that had to be introduced in- 
to the membrane to achieve 50% inhibition of lipid 
peroxidation was approximately 15-fold less than for 
cholesterol. Moreover the IC5o values of 4-hydroxy- 
tamoxifen and 17B-oestradiol were approximately 
200-fold less than for cholesterol. 
Table I 
IC5o values for the inhibition of lipid peroxidation by cholesterol, 
tamoxifen, ergosterol, 4-hydroxytamoxifen a d 17~-oestradiol, each 
introduced into phospholipid liposomes during their preparation 
Compound IC5o 
(mg/ml) (mM) mol /mol  phospholipid 
Cholesterol 2.8 7.2 7.5 x 10- 
Tamoxifen 0.19 0.50 5.3 × 10- 2 
Ergosterol 0.21 0.53 5.4 × 10- 2 
4-Hydroxytamoxifen 0.014 0.036 3.8 x 10-3 
17/3-Oestradiol 0.011 0.040 4.4 × 10 - 3 
Values are deduced from the graphs shown in Fig. 2, in which each 
point represents the mean + SD of 6-9 separate assays. 
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For maximum stabilization against lipid peroxida- 
tion, cholesterol had to be introduced into the mem- 
brane at a molar ratio of approximately 1.0 (see Fig. 2), 
which is in agreement with earlier work [12]. Maximum 
stabilization against lipid peroxidation of membranes 
containing introduced tamoxifen or ergosterol was 
observed at the lower molar ratio of approximately 0.5. 
However, introduced 4-hydroxytamoxifen or 17/3- 
oestradiol exhibited maximum stabilization against 
peroxidation at the greatly lower molar ratio of 0.05. 
Nevertheless, all of these compounds still retained this 
maximum inhibition of lipid peroxidation (via mem- 
brane stabilization) ata molar ratio of 1.0 in agreement 
with the original findings for cholesterol itself [12]. 
4. DISCUSSION 
The stabilization by cholesterol (and its derivatives 
[15]) of membranes against lipid peroxidation is 
thought to occur via an interaction between the 
hydrophobic rings of cholesterol and the saturated, mo- 
nounsaturated and polyunsaturated residues of 
phospholipid fatty acids [12,16], which reduces the 
fluidity of the membrane bilayer [8,9]. We have now 
shown that ergosterol, tamoxifen, 4-hydroxytamoxifen 
and 1713-oestradiol also exert membrane stabilizing ef- 
fects against lipid peroxidation, possibly by a similar 
mechanism tothat for cholesterol. Molecular models of 
the chemical structure of tamoxifen and 4-hydroxy- 
tamoxifen suggest hat these compounds can take up 
conformations that structurally mimic the conforma- 
tions of cholesterol, ergosterol and possibly 17/3- 
oestradiol. 
The molar ratio required for maximum stabilization 
against lipid peroxidation is important in identifying 
the structural relationship between the added com- 
pound and the membrane phospholipid of the 
liposome. The molar ratio of cholesterol to phospho- 
lipid in most animal membranes i  approximately 1.0 
and this ratio in ox-brain phospholipid liposomes offers 
maximum inhibition against lipid peroxidation [12] and 
thus maximum membrane stabilization, a result con- 
firmed in our study. For ergosterol and tamoxifen, 
maximum membrane stabilization was reached at a 
molar ratio of approximately 0.5 (2-fold less than for 
cholesterol) and for 4-hydroxytamoxifen a d 17/3- 
oestradiol only 0.05 (20-fold less than for cholesterol). 
However, the ICso values for these compounds were 
found to be more divergent from the cholesterol value 
and were approximately 15-fold less for tamoxifen and 
ergosterol and approximately 200-fold less for 
4-hydroxytamoxifen and 1713-oestradiol than for 
cholesterol. The ICso values indicate the relationships at
the inflexion points of the curves in Fig. 2, rather than 
those near the maximum of these curves. It is the latter 
data that best reflects the similarity between cholesterol 
and the other compounds introduced into the mem- 
brane that mimic the structural role of cholesterol, in 
their ability to achieve maximum membrane stabiliza- 
tion against lipid peroxidation. The increased efficiency 
of these compounds as shown by the lower molar ratios 
in relation to cholesterol, may result from their interac- 
tion across more than one lipid bilayer in the multilayer 
liposome structure. 
The potent inhibition of lipid peroxidation by 
4-hydroxytamoxifen may reflect the presence of a 
phenolic hydroxyl group in this compound. Indeed the 
acetyl derivative of cholesterol is less effective than 
cholesterol as an inhibitor of lipid peroxidation sug- 
gesting that the hydroxyl group may be important for 
the correct orientation of cholesterol in the phospho- 
lipid bilayer [12]. 
Tamoxifen, 4-hydroxytamoxifen and 17/3-oestradiol 
also show an inhibitory effect on lipid peroxidation 
when added in ethanol externally to preformed 
liposomes [7], whereas cholesterol and ergosterol under 
similar conditions have no activity (H.W., unpublished 
data). This difference may reflect he ease with which 
the drugs and hormones used are able to enter 
liposomes and also natural membranes [7]. 
It is particularly interesting that introduced 
ergosterol is a more powerful stabilizer against lipid 
peroxidation i the liposomal model membrane than in- 
troduced cholesterol. This may suggest an antioxidant 
action against lipid peroxidation that has been retained 
by plant and fungal cells during evolution. 
Tamoxifen and in particular 4-hydroxytamoxifen, 
which has a higher affinity for the oestrogen receptor 
than tamoxifen, can also be considered to be structural 
mimics of 17t3-oestradiol n the basis of their overall 
conformation (see Fig. 1). It is thought hat it is the 
composition and positioning of the side chains of 
tamoxifen and 4-hydroxytamoxifen that give these 
compounds anti-oestrogenic rather than oestrogenic a - 
tivity in breast cancer cells, which is mediated through 
the oestrogen receptor [17]. Similarly, membrane 
stabilization effects would be expected to reflect struc- 
tural mimicry of 1713-oestradiol by tamoxifen and in 
particular 4-hydroxytamoxifen. 
The ability of tamoxifen and 4-hydroxytamoxifen to 
stabilize membranes against lipid peroxidation beyond 
that achieved by cholesterol may reflect a further educ- 
tion in membrane fluidity, which is thought o be 
responsible for this stabilizing ability of cholesterol 
[8,9,12,16]. In the presence of these drugs therefore cell 
division may be slower as a result of reduced membrane 
fluidity, in agreement with the growth inhibitory pro- 
perties of tamoxifen and 4-hydroxytamoxifen o
oestrogen-dependent and oestrogen-independent breast 
tumours in vivo [5,18] and tumour cell lines in vitro 
[5,19,20]. Similarly in the oestrogen-independent y ast 
tumour cell model growth system [21-23] an explana- 
tion of the potent inhibition of growth by tamoxifen 
[22], which may be useful in the treatment of systemic 
109 
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Cand ida  in fect ions  (see [23]), may  reside in the 
de leter ious fur ther  reduct ion  o f  membrane  f lu idi ty 
beyond that  ach ieved even by ergosterol .  
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